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Leiden, the Netherlands
Objectives Our purpose was to evaluate the efficacy and safety of drug-eluting stents in the setting of primary percutaneous
coronary intervention for ST-segment elevation myocardial infarction (STEMI).
Background There is inconsistent and limited evidence about the efficacy and safety of drug-eluting stents in STEMI patients.
Methods A single-blind, single-center, randomized study was performed to compare bare-metal stents (BMS) with
sirolimus-eluting stents (SES) in 310 STEMI patients. The primary end point was in-segment late luminal loss
(LLL) at 9 months. Secondary end points included late stent malapposition (LSM) at 9 months as determined by
intravascular ultrasound imaging and clinical events at 12 months.
Results In-segment LLL was 0.68  0.57 mm in the BMS group and 0.12  0.43 mm in the SES group with a mean
difference of 0.56 mm, 95% confidence interval 0.43 to 0.68 mm (p  0.001). Late stent malapposition at 9
months was present in 12.5% BMS patients and in 37.5% SES patients (p  0.001). Event-free survival at 12
months was 73.6% in BMS patients and 86.0% in SES patients (p  0.01). The target-vessel-failure-free survival
was 84.7% in the BMS group and 93.0% in the SES group (p  0.02), mainly because of a higher target lesion
revascularization rate in BMS patients (11.3% vs. 3.2%; p  0.006). Rates of death, myocardial infarction, and
stent thrombosis were not different.
Conclusions Sirolimus-eluting stent implantation in STEMI patients is associated with a favorable midterm clinical and angio-
graphic outcome compared with treatment with BMS. However, LSM raises concern about the long-term safety of
SES in STEMI patients (MISSION!; ISRCTN62825862). (J Am Coll Cardiol 2008;51:618–26) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.056c
c
i
o
(
c
n
D
r
Iercutaneous coronary intervention (PCI) is the preferred
evascularization strategy in patients presenting with ST-
egment elevation myocardial infarction (STEMI) (1). Per-
rom the *Department of Cardiology, †Department of Medical Statistics and
io-Informatics, and ‡Department of Radiology, Leiden University Medical Center,
eiden, the Netherlands. This study was supported by the Netherlands Heart
oundation and by an unrestricted research grant from Guidant Inc., Nieuwegein, the
etherlands. Dr. Jukema is an established clinical investigator of the Netherlands
eart Foundation (grant 2001D032).t
Manuscript received June 11, 2007; revised manuscript received September 13,
007, accepted September 17, 2007.utaneous coronary intervention is directed at restoring
oronary flow, stabilizing the ruptured plaque, and reducing
nfarct size, thereby improving short- and long-term clinical
utcome. Implantation of a bare-metal coronary artery stent
BMS) during primary PCI further improves outcome
ompared with balloon angioplasty alone by reducing the
umber of acute complications and the restenosis rate (2,3).
rug-eluting stents have been proven effective in reducing
estenosis in patients with stable and unstable angina (4–7).
nconsistent and limited results have been presented about
he efficacy and safety of drug-eluting stents in STEMI
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February 12, 2008:618–26 SES Versus BMS in STEMI Patientsatients (8,9). In particular, stent thrombosis occurring late
fter implantation of drug-eluting stents, possibly related to
ate malapposition of the stent struts, has raised safety
oncerns (10,11). Therefore, this randomized prospective
tudy was designed to evaluate midterm angiographic out-
ome and clinical efficacy of third-generation BMS com-
ared with that seen in sirolimus-eluting stents (SES) in
TEMI patients. To address the issue of late stent malap-
osition (LSM), intravascular ultrasound (IVUS) imaging
as performed in both groups at 9-month follow-up.
ethods
tudy design. This is a single-center, single-blind, ran-
omized prospective noninferiority study to evaluate clini-
al, angiographic, and IVUS results in STEMI patients
reated with either BMS or SES. The study protocol was
pproved by the institutional ethical committee. Written
nformed consent was obtained from all patients before
nrollment and before the follow-up catheterization. Pa-
ients and operators performing the follow-up angiography
ere blinded to the treatment assignment. The study was
onducted from February 2004 to October 2006. During
he study period, all patients were treated according to the
nstitutional STEMI protocol, which included standardized
utpatient follow-up (12).
atient selection. Patients were eligible if STEMI symp-
oms started 9 h before the procedure and the electrocar-
iogram (ECG) demonstrated STEMI (ST-segment eleva-
ion 0.2 mV in 2 contiguous leads in V1 through V3 or
0.1 mV in other leads, or [presumed] new left bundle
ranch block). Furthermore, the target lesion length should
e 24 mm. Exclusion criteria were: 1) age 18 years or
80 years; 2) left main stenosis of 50%; 3) triple-vessel
isease, defined as 50% stenosis in 3 major epicardial
ranches; 4) previous PCI or coronary artery bypass grafting
f the infarct-related artery; 5) thrombolytic therapy for the
ndex infarction; 5) target vessel reference diameter 2.25
m or 3.75 mm; 6) need for mechanical ventilation; 7)
ontraindication to the use of aspirin, clopidogrel, heparin,
r abciximab; 8) known renal failure; or 9) a life expectancy
12 months.
After crossing the target lesion with a guidewire and after
isual estimation of the target vessel reference diameter,
andomization to treatment with a BMS (Vision, Guidant
orp. Indianapolis, Indiana) or SES (Cypher, Cordis
orp., Miami Lakes, Florida) was performed in a 1:1 ratio.
tudy procedure. Before the procedure all patients re-
eived 300 mg of aspirin, 300 to 600 mg of clopidogrel, and
n intravenous bolus of abciximab (25 g/kg), followed by
continuous infusion of 10 g/kg/min for 12 h. At start of
he procedure, 5,000 IU of heparin was given. Lesions were
reated according to current interventional practice. Direct
tenting was allowed. If more than 1 stent was required,
dditional assigned study stents were used. Stent size and
ength selection was based on visual estimation. Before and emmediately after the interven-
ion, 2 angiograms in orthogonal
rojections were obtained. Intra-
ascular ultrasound imaging was
erformed after stent implanta-
ion (motorized pull-back [0.5
m/s]), starting 10 mm distal
o the stent and ending at the
oronary ostium, using a 2.9-F
0-MHz catheter and a dedi-
ated IVUS console (Eagle Eye,
olcano Corp., Rancho Cordova,
alifornia) (13). Intravascular-
ltrasound-guided stenting was
ot performed to reflect routine
ngiographic stent implantation.
ach angiogram and ultrasound
equence was preceded by 200
o 300 g of intracoronary
itroglycerin.
ollow-up and data collection.
atients were seen at the outpa-
ient clinic at 30 days, 3, 6, and
2 months (12). Aspirin (80 to
00 mg/day) was prescribed indefinitely and clopidogrel (75
g/day) for 12 months. Patients were treated with beta-
locking agents, statins, and angiotensin-converting enzyme
nhibitors or angiotensin II blockers. Follow-up angiogra-
hy and IVUS imaging was performed at 9 months.
uantitative coronary angiography (QCA) and IVUS
nalysis. Angiograms were analyzed off-line by analysts
linded for the assigned treatment using validated QCA
ystems (CMS version 6.1, Medis, Leiden, the Nether-
ands). Measurements were made in a single projection
howing the most severe stenosis following standardized
perating procedures (14). The minimal lumen diameter
MLD) was measured, and the percentage diameter stenosis
as calculated using the interpolated reference diameter
pproach. Late luminal loss (LLL) was defined as the
ifference between the post-procedural MLD and follow-up
LD. Angiographic restenosis was defined as 50% di-
meter stenosis at 9-months, follow-up.
Intravascular ultrasound images were analyzed off-line,
sing quantitative IVUS analysis software (QCU-CMS
ersion 4.14, Medis). The stented segment (5 mm prox-
mally and distally to the stent) was analyzed. The stent and
umen boundaries were determined in all individual frames.
n case of malapposition, the stent boundaries were used as
umen boundaries. The volume within the stent and the
uminal volume were calculated applying Simpson’s rule
15). Stent malapposition was defined as a separation of at
east 1 stent strut, not overlapping a side branch, from the
ntimal surface with IVUS evidence of blood speckles
ehind the strut (16,17). The site of malapposition was
lassified as: 1) the body of the stent; 2) the proximal stent
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
HR  hazard ratio
IVUS  intravascular
ultrasound
LLL  late luminal loss
LSM  late stent
malapposition
MI  myocardial infarction
MLD  minimal luminal
diameter
PCI  percutaneous
coronary intervention
QCA  quantitative
coronary angiography
SES  sirolimus-eluting
stent(s)
STEMI  ST-segment
elevation myocardial
infarctiondge; or 3) the distal stent edge. Malapposition was persis-
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SES Versus BMS in STEMI Patients February 12, 2008:618–26ent if it was present immediately after stent implantation
nd at follow-up, and acquired if it was present at follow-up
nly.
tudy end points. The primary end point of the study was
n-segment LLL at 9-month follow-up angiography. Sec-
ndary end points were angiographic restenosis and LSM at
months. Additional secondary end points were death,
yocardial infarction (MI), target vessel revascularization,
arget lesion revascularization, target vessel failure, stent
hrombosis, procedural success, and clinical success. All
eaths were defined as cardiac, unless it was unequivocally
roven noncardiac. Myocardial infarction during follow-up
as defined as a troponin-T rise0.03 g/l with symptoms
r PCI, a rise of troponin-T 0.15 g/l after coronary
rtery bypass grafting, or a rerise of troponin-T 25% after
ecent MI in the presence of symptoms or re-PCI, or the
evelopment of new Q waves on ECG (18,19). All infarc-
ions were categorized as spontaneous or procedure related
nonindex procedure) (18,19). Procedural success was de-
ned as the achievement of 50% diameter stenosis by
CA with achievement of Thrombolysis In Myocardial
nfarction flow grade 3. Clinical success was defined as
rocedural success without death or reinfarction during the
ndex hospitalization. Target vessel and target lesion revas-
ularization were defined as any revascularization procedure
f the target vessel or target lesion (from 5 mm distally to
he stent up to 5 mm proximally to the stent), respectively.
linically driven target lesion revascularization was defined
s repeated revascularization procedure of the target lesion
showing 50% diameter stenosis) driven by clinical symp-
oms at rest in conjunction with electrocardiographic evi-
ence of ischemia or a positive stress test (in the presence or
bsence of clinical symptoms). Target vessel failure was
efined as the composite of cardiac death or recurrent MI
ttributable to the target vessel or any revascularization
rocedure of the target vessel. If events could not unequiv-
cally be attributed to a nonculprit vessel, they were con-
idered culprit vessel related. Stent thrombosis was defined
s angiographically documented thrombus within the stent
nd/or typical chest pain with recurrent ST-segment eleva-
ion in the territory of the infarct-related vessel in combi-
ation with a significant rise of troponin levels and/or the
resence of new Q waves in the territory of the infarct-
elated vessel. Stent thrombosis was classified as acute if it
ccurred 24 h after the index procedure, as subacute if it
ccurred between 1 to 30 days, and as late if it occurred30
ays (9). All clinical events were adjudicated by a clinical
vents committee whose members were blinded for the
ssigned stent type.
tatistical design and analysis. The study objective was to
ssess whether the outcome of treatment with BMS was
oninferior to the outcome of treatment with SES. To
rove noninferiority, a difference of 0.35 mm angio-
raphic in-segment LLL at 9 months was considered
linically insignificant. The sample size to demonstrate
oninferiority of BMS was 244 patients (1-sided) based on 0he following assumptions: 1) angiographic in-segment
LL at 9 months is 0.40 mm in the SES group and 0.60
m in the BMS group, with a common within-group
tandard deviation of 0.40 mm (power 0.90, alpha error of
.05). To compensate for unsuccessful interventions, cross-
vers, and losses to follow-up, the sample size was increased
o a total of 316 patients. All analyses were conducted
ccording to the intention-to-treat principle. Analysis of
ost-procedural and follow-up angiographic and IVUS data
as conducted according to the number of patients for
hich complete data were available. All continuous variables
ere compared between the treatment groups with a t test
r, in case of non-normality as tested by Shapiro-Wilk’s
tatistics, with an equivalent nonparametric test. Categorical
ariables were compared with Pearson’s chi-square test or
isher exact test in case of 1 or more cells in the contingency
able with expectation 5. Event-free and target-vessel-
ailure-free survival were computed using Kaplan-Meier
stimates and compared between treatment groups with the
og-rank test. The hazard ratio (HR) was calculated by Cox
egression with treatment group as sole covariate. To correct
or differences in baseline characteristics, the appropriate
ultivariate analysis was performed. All p values were
-sided, and a p value of less than 0.05 was considered
tatistically significant. All analyses were conducted with
PSS version 12.0.1 statistical analysis software (SPSS Inc.,
hicago, Illinois).
esults
atients. A total of 316 STEMI patients were enrolled
n the study (Table 1, Fig. 1). Six patients were subse-
uently excluded because the assigned study stent was not
vailable, and 310 patients (152 assigned to BMS and
58 assigned to SES) were included in the analysis. With
xception of a larger reference diameter in the BMS
roup, the groups were comparable. One patient crossed
ver from SES to BMS because of the inability to cross
he lesion with the SES. Procedural characteristics are
ummarized in Table 2.
ngiographic results. Post-procedural and follow-up an-
iographic data were available for 124 BMS patients
81.6%) and 131 SES patients (82.9%). Patients with and
ithout follow-up angiography had similar baseline charac-
eristics. Six patients without follow-up angiography died
uring follow-up (4 BMS and 2 SES patients). The median
ime to angiographic follow-up was 272 days (10th to
0th percentiles: 268 to 295 days) in the BMS group and
72 days (10th to 90th percentiles: 270 to 290 days) in
he SES group (p  0.66). Post-procedural and
ollow-up QCA results are summarized in Table 3. The
ean difference between BMS and SES patients in in-
egment LLL was 0.56 mm (95% confidence interval [CI]
.43 to 0.68, p 0.001) at 9 months. This difference remained
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February 12, 2008:618–26 SES Versus BMS in STEMI Patientsignificant after adjustment for baseline characteristics as listed
n Table 1 (mean difference 0.60 mm, 95% CI 0.48 to 0.72, p
0.001). The in-segment angiographic restenosis rate was
2.6% in the BMS group and 3.8% in the SES group (relative
isk 5.92, 95% CI 2.36 to 14.84). The cumulative percentage
iameter stenosis distribution after the procedure and at
ollow-up angiography is shown in Figure 2.
VUS results. Follow-up IVUS results were available for
3 (61.2%) BMS patients and 115 (72.8%) SES patients
p  0.03). Inability to cross the stented segment with the
VUS catheter in patients with significant restenosis was an
mportant reason for the lower number of IVUS studies in
MS patients. Quantitative IVUS data are summarized in
able 4. At follow-up, the minimal luminal area was 4.01
.38 mm2 in the BMS group and 5.67  1.59 mm2 in the
ES group (p  0.001). The percentage neointimal
olume was 27.0  11% in the BMS group and 3.3 
.0% in the SES group (p  0.001). Late stent malap-
Baseline Clinical and Angiographic Characterist
Table 1 Baseline Clinical and Angiographic
Characteristic SES
Age (yrs) 59.
Male gender 118
Diabetes mellitus 20
Current smoker 84
Hypercholesterolemia 37
Hypertension 48
Family history of CAD 73
Prior myocardial infarction 7
Prior PCI 4
Prior CABG 1
Time, min: median (interquartile range)
Symptoms onset to first ECG 88
Symptoms onset to balloon inflation 183
Target vessel
LAD 87
RCA 40
LCX 31
Multivessel disease 56
TIMI flow grade before
0 96
1 18
2 20
3 24
Maximal creatinine phosphokinase, U/l
Median
Interquartile range 86
QCA before procedure
Lesion length, mm 13.
Reference diameter, mm 2.7
Minimal luminal diameter, mm 0.2
Stenosis, % of luminal diameter 91.
Data are expressed as number (%) or mean standard deviation. All co
or Pearson’s chi-square test (categorical variables) except as indicate
BMS  bare-metal stent; CABG  coronary artery bypass grafting; C
descending coronary artery; LCX  left circumflex artery; PCI  perc
RCA  right coronary artery; SES  sirolimus-eluting stent; TIMI  Thosition was present in 12.5% BMS patients and 37.5% TES patients. Late stent malapposition was persistent in
1.3% BMS patients and 18.3% SES patients (p  0.19).
ate stent malapposition was acquired in 5.0% BMS
atients and in 25% SES patients (p  0.001). Acquired
SM within the body of the stent occurred almost
xclusively in SES patients (20.2% vs. 1.3% in BMS
atients, p  0.001).
linical outcome. No patients were lost to follow-up.
dverse events during follow-up are listed in Table 5. The
vent-free survival was 73.6% in BMS patients and 86.0% in
ES patients (HR 1.96, 95% CI 1.17 to 3.30) (Fig. 3A).
uring follow-up 6 patients died (1.9%), 4 BMS patients
nd 2 SES patients (p  0.44). Recurrent MI occurred in
.2% of BMS patients and 5.7% of SES patients (p 0.24);
n 7.2% and in 4.4% of the patients this was related to a
e-PCI procedure, respectively (p  0.29). Spontaneous
I, all related to stent thrombosis, occurred in 2.0% of
MS patients and in 1.3% of SES patients (p  0.68).
cteristics
58) BMS (n  152) p Value
.2 59.1 11.6 0.99
123 (80.9) 0.19
10 (6.6) 0.07
85 (55.9) 0.63
25 (16.4) 0.13
39 (25.7) 0.36
60 (39.5) 0.23
5 (3.3) 0.60
1 (0.7) 0.37*
1 (0.7) 1.00*
3) 106 (71–151) 0.11*
58) 195 (153–257) 0.19*
83 (54.6)
51 (33.6) 0.09
18 (11.8)
50 (32.9) 0.64
90 (59.2)
15 (9.9) 0.87
24 (15.8)
23 (15.1)
2,079 0.25*
3 1,012–3,792
6 15.0 8.6 0.47
54 2.92 0.56 0.02
35 0.27 0.41 0.19*
.6 92.5 12.4 0.35*
ons between groups were performed with t test (continuous variables)
oronary artery disease; ECG  electrocardiogram; LAD  left anterior
us coronary intervention; QCA  quantitative coronary angiography;
ysis In Myocardial Infarction.ics
Chara
(n  1
2 11
(74.7)
(12.7)
(53.2)
(23.4)
(30.4)
(46.2)
(4.4)
(2.5)
(0.6)
(47–15
(133–2
(55.1)
(25.3)
(19.6)
(35.4)
(60.8)
(11.4)
(12.6)
(15.2)
1,844
3–3,41
9 5.
6 0.
1 0.
0 13
mparis
d (*).
AD  carget lesion revascularization rate was 11.2% in BMS
p
c
7
0
t
9
n
w
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SES Versus BMS in STEMI Patients February 12, 2008:618–26atients and 3.2% in SES patients (p  0.006). The
linically driven target lesion revascularization rate was
.9% in BMS patients and 2.5% in SES patients (p 
.03). Target-vessel-failure-free survival was 84.7% in
Figure 1 Patient Flow Chart, Enrollment, and Outcomes
BMS  bare metal stent; CAG  coronary angiography; IVUS  intravascular ultra
QCA  quantitative coronary angiography; SES  sirolimus-eluting stent; TLR  ta
Procedural Characteristics
Table 2 Procedural Characteristics
Characteristic
Direct stenting
Number of stents in the culprit lesion
Implanted stent length, mm
Maximum stent diameter, mm
Maximum balloon diameter, mm
Maximal balloon pressure, bar
Maximal balloon-to-artery ratio
TIMI flow grade after
0
1
2
3
Abciximab therapy
Multivessel intervention during the index procedure
Procedural success
Clinical success
Data are expressed as number (%) or mean standard deviation. All co
or Pearson’s chi-square test (categorical variables) except as indicated (*).
Abbreviations as in Table 1.he BMS group and 93.0% in the SES group (HR 2.24,
5% CI 1.09 to 4.60) (Fig. 3B). Clinical event rates were
ot significantly different between patients who under-
ent follow-up angiography and patients who did not.
;
sion revascularization.
(n  158) BMS (n  152) p Value
7 (36.1) 59 (38.8) 0.62
34 0.61 1.38 0.63 0.57*
.5 12.8 26.4 11.1 0.95*
31 0.26 3.37 0.35 0.05
37 0.31 3.40 0.30 0.30
.3 2.5 12.2 3.0 0.70
17 0.17 1.15 0.19 0.26
1 (0.6) 0 (0.0)
1 (0.6) 1 (0.7) 1.00*
0 (6.4) 10 (6.6)
6 (92.4) 141 (92.7)
8 (100.0) 151 (99.3) 0.49*
0 (6.3) 8 (5.3) 0.69
6 (92.4) 141 (92.8) 0.90
6 (92.4) 140 (92.1) 0.92
ons between groups were performed with t test (continuous variables)sound
rget leSES
5
1.
26
3.
3.
12
1.
1
14
15
1
14
14
mparis
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ompared with treatment with BMS, both in-segment
LL and target vessel failure rates were significantly lower
fter treatment with SES in patients with acute MI.
owever, after SES implantation LSM was seen more often
han after implantation of BMS.
ngiographic results. Angiographic in-segment LLL at
-months’ follow-up was chosen as the primary end point,
ince it reflects the luminal response of the treated segment,
ncluding the segments just outside the stent. Late luminal
oss is a surrogate but powerful end point to compare the
fficacy of stents for the prevention of restenosis (20).
n-segment LLL in the SES group was comparable to the
LL found in the angiographic subgroup of the recently
ublished TYPHOON (Trial to Assess the Use of the
ypher Stent in Acute Myocardial Infarction Treated With
Results of Quantitative Coronary Angiography P
Table 3 Results of Quantitative Coronary An
Characteristic SES (n 
Post-procedure
Stented segment length, mm 22.3 1
Reference diameter, mm 2.94 0
Minimal luminal diameter, mm
In-segment 2.36 0
In-stent 2.67 0
Proximal margin 2.84 0
Distal margin 2.35 0
Stenosis, % of luminal diameter
In-segment 20.0 8
In-stent 11.1 6
Proximal margin 11.4 9
Distal margin 15.1 1
Follow-up
Reference diameter, mm 2.96 0
Minimal luminal diameter, mm
In-segment 2.24 0
In-stent 2.48 0
Proximal margin 2.64 0
Distal margin 2.33 0
Late luminal loss, mm
In-segment 0.12 0
In-stent 0.19 0
Proximal margin 0.20 0
Distal margin 0.03 0
Stenosis, % of luminal diameter
In-segment 24.3 1
In-stent 16.2 1
Proximal margin 16.0 1
Distal margin 15.0 1
Angiographic restenosis
In-segment 5 (3.8
In-stent 3 (2.3
Proximal margin 1 (0.9
Distal margin 1 (0.8
Data are expressed as number (%) or mean standard deviation. All c
(*).
Abbreviations as in Table 1.ngioplasty) (9). The SES LLL was in fact comparable to She LLL in stable angina patients and superior to LLL
chieved with BMS in other STEMI studies (2,5,6). The
ate of LLL in the BMS group was slightly higher than in
he TYPHOON study, which may be explained by the
onger implanted stent length in our study.
VUS results. As in patients with stable angina, SES
reatment in STEMI patients is associated with negligible
eointimal hyperplasia, whereas BMS treatment is associ-
ted with significant hyperplasia at follow-up (21). This
nding explains the low angiographic in-stent restenosis
ate in the SES group. However, despite excellent angio-
raphic results, a significant rate of LSM (37.5%) was
bserved in the SES group. The majority of these malap-
ositions was not present immediately after implantation
ut developed during follow-up, predominantly along the
ody of the stent (20.2%). The rate of LSM after SES in
rocedure and at Follow-Up
raphy Post-Procedure and at Follow-Up
BMS (n  124) p Value
22.6 8.4 0.77*
3.02 0.53 0.20
2.41 0.52 0.44
2.71 0.37 0.33
2.95 0.58 0.15
2.40 0.56 0.49
20.4 9.1 0.67
12.4 7.2 0.14
10.8 9.7 0.64
14.9 10.8 0.91
2.92 0.50 0.59
1.74 0.59 0.001
1.77 0.59 0.001
2.60 0.62 0.67
2.24 0.60 0.26
0.68 0.57 0.001
0.95 0.55 0.001
0.34 0.48 0.01
0.16 0.45 0.007
40.8 17.5 0.001
39.7 18.0 0.001
16.6 12.7 0.71
17.4 14.5 0.16
28 (22.6) 0.001
28 (22.6) 0.001
2 (1.9) 0.61
2 (1.7) 0.61
sons between groups were performed with a t test except as indicatedost-P
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16.3%) and RAVEL (A Randomized Comparison of a
irolimus-Eluting Stent With a Standard Stent for Coro-
ary Revascularization) (21%) studies, both comparing SES
ith BMS in patients with stable and unstable angina
Figure 2 Cumulative Rate of In-Segment
Percentage Diameter Stenosis
Abbreviations as in Figure 1.
esults of Coronaryltrasound Analysis at Follow-Up
Table 4 Results of CoronaryUltrasound Analysis at Follow-Up
Characteristic SES (n  115) BMS (n  93) p Value
Area, mm2
Minimal stent area 6.05 1.56 6.54 1.41 0.02
In-stent MLA 5.67 1.59 4.01 1.38 0.001
Proximal margin MLA 6.81 2.15 6.57 2.53 0.55
Distal margin MLA 5.77 2.09 5.52 2.10 0.45
Volume, mm3
Stent volume 188 86 199 77 0.32
Lumen volume 181 81 145 60 0.001
Neointimal volume 7 12 54 31 0.001*
Percentage neointimal
volume
3.3 5.0 27.0 11.0 0.001*
Late stent malapposition†
Number evaluated 104 80
Any site‡ 39 (37.5) 10 (12.5) 0.001
Persistent 19 (18.3) 9 (11.3) 0.19
Acquired 26 (25.0) 4 (5.0) 0.001*
Proximal stent edge 17 (16.3) 7 (8.8) 0.13
Persistent 14 (13.5) 7 (8.8) 0.32
Acquired 3 (2.9) 0 (0.0) 0.26*
Stent body 27 (26.0) 2 (2.5) 0.001*
Persistent 6 (5.8) 1 (1.3) 0.14*
Acquired 21 (20.2) 1 (1.3) 0.001*
Distal stent edge 13 (12.5) 4 (5.0) 0.08*
Persistent 6 (5.8) 2 (2.5) 0.47*
Acquired 7 (6.7) 2 (2.5) 0.30*
ata are expressed as number (%) or mean standard deviation. All comparisons between groups
ere performed with t test (continuous variables) or Pearson’s chi-square test (categorical
ariables) except indicated (*); †Data are presented for patients with paired (post-procedural and
ollow-up) intravascular ultrasound results; ‡Some patients had both persistent and acquired latew
tent malapposition (6 SES, 3 BMS).
MLA  minimal luminal area; other abbreviations as in Table 1.5,22). In line with our findings, acquired LSM in the
IRIUS study was also mainly located alongside the body of
tent (22). There are only limited data about LSM after
tenting in STEMI patients. Hong et al. (23) reported an
SM rate of 11.5% after BMS implantation. In contrast,
SM after drug-eluting stent implantation was present in
1.8% in an observational study of the same group (24).
ate stent malapposition may be caused by 3 different
actors: 1) insufficient stent deployment during implanta-
ion; 2) resolution of thrombus and/or plaque behind the
tent; or 3) positive remodeling of the vessel wall. Persistent
SM, mainly involving the proximal or distal edges of the
tents, may be caused by insufficient stent deployment and is
hought to be of minor clinical importance (23). In contrast,
cquired LSM, especially when located along the body of
he stent, may be due to an adverse effect of the drug on the
essel wall resulting in positive remodeling. This type of
SM cannot be avoided during stent implantation and
aises concern about long-term safety, as LSM has been
elated to very late (1 year) stent thrombosis (11,25).
linical outcome. The reduction of target vessel failure
ate after SES implantation in STEMI patients was in line
linical Events During 12-Months Follow-Up
Table 5 Clinical Events During 12-Months Follow-Up
Event SES (n  158) BMS (n  152) p Value
Death 2 (1.3) 4 (2.6) 0.44*
Noncardiac — 2 (1.3) 0.24*
Cardiac 2 (1.3) 2 (1.3) 1.00*
Target vessel related 2 (1.3) 2 (1.3) 1.00*
Recurrent myocardial infarction 9 (5.7) 14 (9.2) 0.24
Spontaneous 2 (1.3) 3 (2.0) 0.68*
Target vessel related 2 (1.3) 3 (2.0) 0.68*
Procedure related 7 (4.4) 11 (7.2) 0.29
Target vessel related 2 (1.3) 6 (3.9) 0.17*
Revascularization procedure† 19 (12.0) 35 (23.0) 0.01
PCI 17 (10.8) 30 (19.7) 0.03
CABG 2 (1.3) 5 (3.3) 0.28*
Target vessel revascularization† 8 (5.1) 20 (13.2) 0.01
PCI 6 (3.8) 17 (11.2) 0.01
CABG 2 (1.3) 3 (2.0) 0.68*
Target lesion revascularization† 5 (3.2) 17 (11.2) 0.006
PCI 3 (1.9) 14 (9.2) 0.005
CABG 2 (1.3) 3 (2.0) 0.68*
Clinically driven 4 (2.5) 12 (7.9) 0.03
Any event 22 (13.9) 40 (26.3) 0.01‡
Target vessel failure 11 (7.0) 23 (15.1) 0.02‡
Stent thrombosis 2 (1.3) 3 (2.0) 0.68*
Acute (24 h) — — —
Subacute (1 day to 30 days) 2 (1.3) 2 (1.3) 1.00*
Late (30 days) — 1 (0.7) 0.49*
Angiographically documented 1 (0.6) 1 (0.7) 1.00*
ata are expressed as number (%). All comparisons between groups were performed with
earson’s chi-square test (categorical variables), except as indicated (Fisher exact test*; log-rank
est‡); †If the patient underwent more than 1 procedure, for every type of revascularization
rocedure (revascularization, target vessel revascularization, or target lesion revascularization) the
rst event per patient was counted.
Abbreviations as in Table 1.ith the results of the TYPHOON study (9). In contrast,
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February 12, 2008:618–26 SES Versus BMS in STEMI Patientshe PASSION (Paclitaxel Eluting Stent Versus Conven-
ional Stent in ST-Segment Elevation Myocardial Infarc-
ion) study, comparing paclitaxel-eluting stents and BMS in
TEMI patients, failed to demonstrate a reduction in the
arget vessel failure rate in the paclitaxel-eluting stent
roup (8). This difference may be explained by differences
n baseline characteristics such as a larger reference
iameter and shorter implanted stent length, differences
n stent design and drug efficacy, or the lack of angiographic
ollow-up in the PASSION study (26).
Mortality and MI rates were low in both groups. The MI
ate was slightly higher than in the TYPHOON study,
ossibly because of the strict definitions used in our study.
f interest, the stent thrombosis rate at 12 months was
ower and comparable to the results of the STRATEGY
Figure 3 Event Free and TVF Free Survival
(A) Kaplan-Meier estimates of survival free from any events among patients
treated with BMS and those treated with SES. The event-free survival was sig-
nificantly higher in the SES group than the BMS group (p  0.01). (B) Kaplan-
Meier estimates of survival free from target vessel failure (TVF) among patients
treated with BMS and those treated with SES. The TVF free survival was signifi-
cantly higher in the SES group than the BMS group (p  0.02). Abbreviations
as in Figure 1.Single High-Dose Bolus Tirofiban and Sirolimus-Eluting
mtent vs. Abciximab and Bare-Metal Stent in Myocardial
nfarction) study (comparing SES with tirofiban and BMS
ith abciximab in STEMI patients) (27). There were no
ases of acute stent thrombosis (24 h), possibly because of
he intensive antithrombotic regimen applied, including the
dministration of abciximab in all patients. Late stent
hrombosis (30 days) occurred in 1 BMS patient (0.7%).
tudy limitations. With regard to the outcome, the non-
nferiority design of the study is a relative limitation (28). At
he time of conception of the study, only limited informa-
ion about the efficacy of SES and third-generation BMS in
TEMI patients was available. It was assumed that, despite
imited differences in late loss, third-generation BMS were
ot inferior to drug-eluting stents with regard to efficacy,
hereas adverse effects of drug-eluting stents such as LSM
nd delayed re-endothelialization could be avoided by using
MS (11). Another limitation is that the angiographic and
linical results of this study cannot be translated into general
aily clinical practice, as this was a single-center study in
elected patients, and patients were followed using a strict
uideline-based follow-up protocol, which is not common
ractice yet. Moreover, this study was underpowered to
etect differences in safety events such as death, recurrent
I, or stent thrombosis. Since IVUS follow-up was not
ossible in some BMS patients because of restenosis, we
annot exclude that LSM was underestimated in the BMS
roup, although this is unlikely since these patients had
ore neointimal growth. Finally, we cannot exclude that
he routine angiographic follow-up did result in additional
evascularization procedures, magnifying the difference in
linical outcome between BMS and SES.
onclusions
he SES implantation in STEMI patients is associated
ith superior midterm clinical and angiographic results
ompared with BMS implantation. However, LSM is
requently observed in STEMI patients treated with SES,
aising concern about long-term safety warranting long-
erm clinical follow-up. Therefore, based on this study, we
annot recommend or discourage SES use in STEMI
atients.
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